Elevation Oncology Inc (ELEV)
0.5801
-0.04
(-6.21%)
USD |
NASDAQ |
Nov 14, 16:00
0.5802
0.00 (0.00%)
After-Hours: 17:50
Elevation Oncology Enterprise Value: -35.48M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -35.48M |
| November 12, 2024 | -31.30M |
| November 11, 2024 | -32.44M |
| November 08, 2024 | -33.63M |
| November 07, 2024 | -37.93M |
| November 06, 2024 | -39.53M |
| November 05, 2024 | -38.94M |
| November 04, 2024 | -41.15M |
| November 01, 2024 | -40.36M |
| October 31, 2024 | -38.10M |
| October 30, 2024 | -36.58M |
| October 29, 2024 | -36.99M |
| October 28, 2024 | -36.83M |
| October 25, 2024 | -37.64M |
| October 24, 2024 | -35.15M |
| October 23, 2024 | -36.54M |
| October 22, 2024 | -33.40M |
| October 21, 2024 | -37.45M |
| October 18, 2024 | -38.01M |
| October 17, 2024 | -39.46M |
| October 16, 2024 | -39.40M |
| October 15, 2024 | -41.37M |
| October 14, 2024 | -41.56M |
| October 11, 2024 | -41.75M |
| October 10, 2024 | -42.44M |
| Date | Value |
|---|---|
| October 09, 2024 | -41.48M |
| October 08, 2024 | -41.17M |
| October 07, 2024 | -39.98M |
| October 04, 2024 | -40.22M |
| October 03, 2024 | -41.27M |
| October 02, 2024 | -38.07M |
| October 01, 2024 | -38.92M |
| September 30, 2024 | -36.58M |
| September 27, 2024 | -45.06M |
| September 26, 2024 | -45.92M |
| September 25, 2024 | -45.77M |
| September 24, 2024 | -44.81M |
| September 23, 2024 | -45.93M |
| September 20, 2024 | -45.30M |
| September 19, 2024 | -44.48M |
| September 18, 2024 | -44.81M |
| September 17, 2024 | -44.26M |
| September 16, 2024 | -43.88M |
| September 13, 2024 | -43.95M |
| September 12, 2024 | -43.88M |
| September 11, 2024 | -44.26M |
| September 10, 2024 | -43.89M |
| September 09, 2024 | -42.70M |
| September 06, 2024 | -42.99M |
| September 05, 2024 | -41.51M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-102.76M
Minimum
Jun 16 2022
220.84M
Maximum
Jun 29 2021
-3.132M
Average
-36.05M
Median
Dec 13 2021
Enterprise Value Benchmarks
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
| NovaBay Pharmaceuticals Inc | 3.432M |
| Protalix BioTherapeutics Inc | 66.58M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.88M |
| Total Expenses (Quarterly) | 13.23M |
| EPS Diluted (Quarterly) | -0.22 |
| Earnings Yield | -143.1% |